Generic
Sotagliflozin
1 brands available in the market
At a glance
Sotagliflozin is an SGLT1 and SGLT2 inhibitor used as an adjunct to insulin therapy to improve glycemic control in type 1 diabetes mellitus (BMI ≥27 kg/m² with inadequate glycemic control despite optimal insulin therapy).
Description
Sotagliflozin is an orally delivered dual inhibitor of SGLT1 and SGLT2. SGLT1 inhibition delays and reduces glucose absorption in the intestine, blunting postprandial hyperglycemia. SGLT2 inhibition reduces renal glucose reabsorption and lowers the renal threshold for glucose, increasing urinary glucose excretion.
Indications
- Type 1 diabetes mellitus (BMI ≥27 kg/m², inadequate glycemic control despite optimal insulin therapy)
Therapeutic class
SGLT2 & SGLT1 Inhibitors
Pharmacological class
Dual SGLT1/SGLT2 Inhibitor
Pharmacology
Sotagliflozin inhibits both SGLT1 and SGLT2. SGLT1 inhibition reduces intestinal glucose absorption, blunting postprandial glucose spikes. SGLT2 inhibition reduces renal glucose reabsorption in the proximal tubule, increasing urinary glucose excretion and lowering blood glucose levels.
Mechanism of action
Reduces glucose absorption and increases urinary glucose excretion by inhibiting SGLT1 and SGLT2.
Dosage
Adult Dose (Oral):
- Recommended: 200 mg once daily (before the first meal of the day)
- If additional glycemic control is needed: Increase to 400 mg once daily after at least 3 months
Administration
- Take orally (before the first meal of the day)
- Take at the same time each day
- Take as directed by a physician
Missed dose
If you miss a dose, take it as soon as you remember; if almost time for the next dose, skip it; do not double the dose.
Side effects
Side Effects:
- Hypotension
- Renal impairment
- Hepatic impairment
- Genital mycotic infections
- Urinary tract infections
- Nausea, vomiting, abdominal pain
- Excessive thirst, constant fatigue
- Ketonuria or elevated beta-hydroxybutyrate
- Rapid weight loss
Precautions & warnings
- Risk of hypoglycemia with insulin (may require insulin dose reduction)
- Hypotension: Assess volume status in elderly, renal impairment, low systolic BP, patients on diuretics
- eGFR <60: Not recommended to initiate; discontinue if eGFR <45
- Do not use in moderate-severe hepatic impairment
Contraindications
- Hypersensitivity to active substance or any excipient
Drug interactions
- Insulin: Increased risk of hypoglycemia; insulin dose reduction may be required
- Metformin, metoprolol, midazolam, oral contraceptives: No clinically relevant effect
Food interactions
Caution is advised when consuming alcohol with Sotagliflozin; consult your doctor.
Use in pregnancy
Use in Pregnancy: No data available on use in pregnant women; consult your doctor.
Pregnancy Category: C — always consult a doctor before taking during pregnancy.
Use in lactation
Use in Lactation: No data on excretion into human milk; consult your doctor.
Pediatric use
Safety and efficacy not established in children
Geriatric use
Elderly: Higher risk of hypotension; caution required
Renal / hepatic impairment
Renal Impairment: eGFR <60: Do not initiate; eGFR <45: Discontinue; consult your doctor.
Hepatic Impairment: Do not use in moderate-severe hepatic impairment; consult your doctor.
Overdose effects
Multiple doses up to 800 mg/day were well tolerated; in overdose, provide symptomatic supportive treatment; removal by hemodialysis has not been studied.
Storage conditions
Store below 30°C; keep away from light; keep out of reach of children.
Chemical structure
Sotagliflozin